Skip to main content

Interleukin-6 May Boost Prediction of Obesity-Related Cancers

By Lori Solomon HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on Sep 3, 2024.

via HealthDay

TUESDAY, Sept. 3, 2024 -- In patients with newly diagnosed type 2 diabetes, baseline interleukin-6 (IL-6) levels may enhance prediction of new-onset obesity-related cancers, according to a study scheduled to be presented at the annual meeting of the European Association for the Study of Diabetes, being held from Sept. 9 to 13 in Madrid.

Mathilde Dahlin Bennetsen, from the Steno Diabetes Center Odense at Odense University Hospital in Denmark, and colleagues explored whether IL-6, tumor necrosis factor-alpha (TNF-α), and high-sensitivity C-reactive protein (hsCRP) can serve as predictive biomarkers for obesity-related cancers in patients recently diagnosed with type 2 diabetes. The analysis included 6,466 individuals followed for a median 8.8 years.

The researchers found that baseline IL-6 levels were associated with a higher subsequent obesity-related cancer risk. A one standard deviation increase in log-transformed IL-6 was tied to a 19 percent increased risk for obesity-related cancers in an adjusted analysis (hazard ratio, 1.19; 95 percent confidence interval, 1.07 to 1.31). There was no strong association seen between TNF-α (hazard ratio, 1.08; 95 percent confidence interval, 0.98 to 1.19) or hsCRP (hazard ratio, 1.08; 95 percent confidence interval, 0.97 to 1.21) and obesity-related cancers. In 4,335 participants with available smoking habit information, similar associations were seen. The addition of IL-6 to a cancer prediction model conferred a small but statistically significant increase in the C-index, from 0.685 to 0.693, whereas the addition of hsCRP or TNF-α did not result in improvements in model performance.

"Understanding which individuals are at higher risk for these cancers would allow for more targeted and effective monitoring and early detection, potentially improving outcomes through earlier intervention and personalized treatment," Bennetsen said in a statement.

Abstract

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Read this next

Uterine Cancer Incidence, Mortality Expected to Increase Through 2050

TUESDAY, July 8, 2025 -- Uterine cancer incidence and mortality rates are projected to increase significantly through 2050, according to a study published online July 1...

Adiposity-Linked Breast Cancer Risk Higher for Women With CVD

MONDAY, July 7, 2025 -- Women with cardiovascular disease (CVD) have a substantially higher adiposity-associated risk for breast cancer, according to a study published online July...

Weight Loss Continues Five Years After Tummy Tucks

THURSDAY, July 3, 2025 -- Patients undergoing abdominoplasty experience continued weight loss up to five years postoperatively, according to a study published in the July issue...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.